Perfuse Therapeutics

News

Bayer has agreed terms for its first biopharma takeover in years, paying $300m upfront for Perfuse and its novel drug implant for eye diseases.

News

Johnson & Johnson's multiple myeloma regimen is now approved as a second line treatment in both the US and the EU.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.